Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. (Q33745075)
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. |
scientific article |
Statements
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors (English)
E Weisberg
Q Liu
Erik Nelson
A L Christie
R Bronson
M Sattler
T Sanda
Z Zhao
W Hur
C Mitsiades
R Smith
J F Daley
R Stone
I Galinsky
J D Griffin
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference